Sorafenib induced sperm shape abnormalities in male swiss albino mice

Surekha Devadasa Shetty, K. Laxminarayana Bairy

Research output: Contribution to journalArticle

Abstract

Sorafenib is a multi-targeted kinase inhibitor. It inhibits the action of vascular endothelial growth factor (VEGE) and is an angiogenesis inhibition. Male gonadal toxicity is common complications of modern anti-cancer treatments. Anti-cancer drugs have adverse effects on spermatogenesis. This study was planned to assess the effects of sorafenib on sperm morphology assay. Male Swiss albino mice were segregated into control, positive control and three treatment groups. Positive control received imatinib (100 mg/kg body weight) and treatment groups received 25, 50 and 100 mg/kg body weight of sorafenib orally for seven consecutive days at intervals of 24 hours between two administrations. Control group remained in home cage for equiduration of time to match their corresponding treatment groups. The animals were sacrificed at the end of 1st, 2nd, 4th, 5th, 7th and 10th weeks after the last exposure to drug respectively. Sperms from epididymis were stained as per standard protocol and 1000 sperms per rat were counted and analysed. There was significant increase in head and tail sperm abnormality. Sorafenib does affect on sperm morphology assay significantly, but this effect is reversible once the drug is withdrawn.

Original languageEnglish
Pages (from-to)950-955
Number of pages6
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume6
Issue number3
Publication statusPublished - 01-01-2015

Fingerprint

Spermatozoa
Assays
Body Weight
Pharmaceutical Preparations
Sperm Tail
Sperm Head
Oncology
Epididymis
Spermatogenesis
Vascular Endothelial Growth Factor A
Toxicity
Rats
Neoplasms
Animals
Phosphotransferases
Control Groups
sorafenib

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{bcb9c8dacf344550bf23b414ba46e876,
title = "Sorafenib induced sperm shape abnormalities in male swiss albino mice",
abstract = "Sorafenib is a multi-targeted kinase inhibitor. It inhibits the action of vascular endothelial growth factor (VEGE) and is an angiogenesis inhibition. Male gonadal toxicity is common complications of modern anti-cancer treatments. Anti-cancer drugs have adverse effects on spermatogenesis. This study was planned to assess the effects of sorafenib on sperm morphology assay. Male Swiss albino mice were segregated into control, positive control and three treatment groups. Positive control received imatinib (100 mg/kg body weight) and treatment groups received 25, 50 and 100 mg/kg body weight of sorafenib orally for seven consecutive days at intervals of 24 hours between two administrations. Control group remained in home cage for equiduration of time to match their corresponding treatment groups. The animals were sacrificed at the end of 1st, 2nd, 4th, 5th, 7th and 10th weeks after the last exposure to drug respectively. Sperms from epididymis were stained as per standard protocol and 1000 sperms per rat were counted and analysed. There was significant increase in head and tail sperm abnormality. Sorafenib does affect on sperm morphology assay significantly, but this effect is reversible once the drug is withdrawn.",
author = "Shetty, {Surekha Devadasa} and {Laxminarayana Bairy}, K.",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "950--955",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "3",

}

Sorafenib induced sperm shape abnormalities in male swiss albino mice. / Shetty, Surekha Devadasa; Laxminarayana Bairy, K.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 6, No. 3, 01.01.2015, p. 950-955.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sorafenib induced sperm shape abnormalities in male swiss albino mice

AU - Shetty, Surekha Devadasa

AU - Laxminarayana Bairy, K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Sorafenib is a multi-targeted kinase inhibitor. It inhibits the action of vascular endothelial growth factor (VEGE) and is an angiogenesis inhibition. Male gonadal toxicity is common complications of modern anti-cancer treatments. Anti-cancer drugs have adverse effects on spermatogenesis. This study was planned to assess the effects of sorafenib on sperm morphology assay. Male Swiss albino mice were segregated into control, positive control and three treatment groups. Positive control received imatinib (100 mg/kg body weight) and treatment groups received 25, 50 and 100 mg/kg body weight of sorafenib orally for seven consecutive days at intervals of 24 hours between two administrations. Control group remained in home cage for equiduration of time to match their corresponding treatment groups. The animals were sacrificed at the end of 1st, 2nd, 4th, 5th, 7th and 10th weeks after the last exposure to drug respectively. Sperms from epididymis were stained as per standard protocol and 1000 sperms per rat were counted and analysed. There was significant increase in head and tail sperm abnormality. Sorafenib does affect on sperm morphology assay significantly, but this effect is reversible once the drug is withdrawn.

AB - Sorafenib is a multi-targeted kinase inhibitor. It inhibits the action of vascular endothelial growth factor (VEGE) and is an angiogenesis inhibition. Male gonadal toxicity is common complications of modern anti-cancer treatments. Anti-cancer drugs have adverse effects on spermatogenesis. This study was planned to assess the effects of sorafenib on sperm morphology assay. Male Swiss albino mice were segregated into control, positive control and three treatment groups. Positive control received imatinib (100 mg/kg body weight) and treatment groups received 25, 50 and 100 mg/kg body weight of sorafenib orally for seven consecutive days at intervals of 24 hours between two administrations. Control group remained in home cage for equiduration of time to match their corresponding treatment groups. The animals were sacrificed at the end of 1st, 2nd, 4th, 5th, 7th and 10th weeks after the last exposure to drug respectively. Sperms from epididymis were stained as per standard protocol and 1000 sperms per rat were counted and analysed. There was significant increase in head and tail sperm abnormality. Sorafenib does affect on sperm morphology assay significantly, but this effect is reversible once the drug is withdrawn.

UR - http://www.scopus.com/inward/record.url?scp=84938780245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938780245&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 950

EP - 955

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 3

ER -